Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.03.02.22271710: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was approved by the institutional review boards of University Hospital de La Princesa, Madrid, Spain, Servicio Departamental de Salud de Chuquisaca in Bolivia, and Instituto Nacional de Higiene “Rafael Rangel” in Venezuela. Sex as a biological variable Eligibility criteria: Healthcare workers aged 18 to 70 years were eligible if they did not have a prior diagnosis of SARS-CoV-2 infection, did not have symptoms compatible with SARS-CoV-2 infection, had a negative IgM/IgG test for SARS-CoV-2, had a negative HIV and (for women) pregnancy tests, a normal electrocardiogram (ECG), and no history of prolongation of the QT interval, maculopathy, impaired renal function, or … SciScore for 10.1101/2022.03.02.22271710: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was approved by the institutional review boards of University Hospital de La Princesa, Madrid, Spain, Servicio Departamental de Salud de Chuquisaca in Bolivia, and Instituto Nacional de Higiene “Rafael Rangel” in Venezuela. Sex as a biological variable Eligibility criteria: Healthcare workers aged 18 to 70 years were eligible if they did not have a prior diagnosis of SARS-CoV-2 infection, did not have symptoms compatible with SARS-CoV-2 infection, had a negative IgM/IgG test for SARS-CoV-2, had a negative HIV and (for women) pregnancy tests, a normal electrocardiogram (ECG), and no history of prolongation of the QT interval, maculopathy, impaired renal function, or immunosuppressive or hematologic conditions. Randomization EPICOS (NCT04334928, EudraCT number 2020-001385-11) was a multicenter, double-blind, placebo-controlled randomized trial to study the effect of TDF/FTC and HCQ as pre-exposure prophylaxis for symptomatic COVID-19 among healthcare workers in Spain, Bolivia and Venezuela. Blinding Investigators, participants, and the data analyst were unaware of treatment assignment. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources In each visit, they were evaluated for the presence of adverse events, received standard laboratory tests, IgM/IgG antibody test for SARS-CoV-2, and an ECG if necessary. SARS-CoV-2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04334928 Completed Randomized Clinical Trial for the Prevention of SARS-CoV-2 I… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
-
